US Patent

US10617696 — Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same

Composition of Matter · Assigned to Clarus Therapeutics Inc · Expires 2030-04-12 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a pharmaceutical formulation of testosterone undecanoate for treating testosterone deficiency or its symptoms.

USPTO Abstract

A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
US10617696
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-04-12
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Clarus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.